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Is Systematic Nodal Dissection Always Essential?
Giulia Veronesi, MD,* Patrick Maisonneuve, ING,† Giuseppe Pelosi, MD,‡ Monica Casiraghi, MD,*
Bernardo G. Agoglia, MD,* Alessandro Borri, MD,* Laura L. Travaini, MD,§
Massimo Bellomi, MD,¶ Cristiano Rampinelli, MD, Daniela Brambilla, MSc,*
Raffaella Bertolotti, MSc,* and Lorenzo Spaggiari, MD*¶
Background: To address whether systematic lymph node dissection
is always necessary in early lung cancer, we identified factors
predicting nodal involvement in a screening series and applied them
to nonscreening-detected cancers.
Methods: In the 97 patients with clinical T1–2N0M0 lung cancer
(3 cm), enrolled in the Continuous Observation of Smoking
Subjects computed tomography (CT) screening study, who under-
went curative resection with radical mediastinal lymph node dissec-
tion, we examined factors associated with hilar extrapulmonary and
mediastinal nodal involvement. Nodule size plus positive/negative
positron emission tomography (PET)-CT (usually as maximum
standard uptake value [maxSUV]) were subsequently evaluated
retrospectively for their ability to predict nodal involvement in 193
consecutive patients with nonscreening-detected clinical stage I lung
cancer.
Results: Among Continuous Observation of Smoking Subjects
patients, 91 (94%) were pN0, and six (6.2%) were pN. All patients
with maxSUV 2.0 (p  0.08) or pathological nodule 10 mm
(p  0.027) were pN0 (62 cases). Nodal metastases occurred in 6
cases among the 29 (17%) patients with lung nodule 10 mm and
maxSUV 2.0 (p  0.002 versus the other 62 cases). In the
nonscreening series, 42 of 43 cases with negative PET-CT (usually
maxSUV 2.0) or nodule 10 mm were pN0; 33 of 149 (22%)
cases with positive PET-CT (usually maxSUV  2.0) and nodule
10 mm were pN (p  0.001 versus the 43 cases).
Conclusions: This limited experience suggests that in early-stage
clinically N0 lung cancers with maxSUV 2.0 or pathological
nodule size 10 mm, systematic nodal dissection can be avoided as
the risk of nodal involvement is very low.
Key Words: Positron emission tomography/computed tomography,
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(J Thorac Oncol. 2011;6: 525–530)
With advances in imaging technology and the introduc-tion of lung cancer screening, many more early-stage
lung cancers are being diagnosed than in the past.1–3 In our
Continuous Observation of Smoking Subjects (COSMOS)
screening study,2 more than 80% of the lung cancers diag-
nosed were stage I or II, and most were less than 1 cm in
diameter. Very early-stage lung cancers may be less aggres-
sive than those conventionally diagnosed,4 suggesting that a
less aggressive surgical approach that reduces morbidity and
improves quality of life might be appropriate, provided cure
rate can be maintained. A less aggressive surgical approach
might also enhance the effectiveness of computed tomogra-
phy (CT) screening,5 reducing the duration and complications
of surgery,6 and overall cost of screening.
The current standard surgical treatment for localized
non-small cell lung cancer (NSCLC) is lobectomy or pneu-
monectomy,7–9 irrespective of the size of the tumor or its
metabolic features on positron emission tomography (PET).
Nevertheless, this approach may be overtreatment for very
small cancers.10,11 Similarly, systematic nodal dissection,
considered essential for accurate intrathoracic staging of
NSCLC,12–16 may be unnecessary in selected clinical stage I
cases, as most are N0.17 If N0 cases could be reliably
identified before nodal dissection, systematic nodal dissection
could be avoided. A reliable preoperative predictor of N0
disease would also have implications for future studies ana-
lyzing the role of limited resection in very early peripheral
lung cancers.
To address the issue of systematic lymph node dissec-
tion in early lung cancer, we analyzed a consecutive series of
patients with clinically N0 screening-detected lung cancer
(including cases other than NSCLC) who underwent preop-
erative staging with 18F-fluorodeoxyglucose (FDG) PET/CT,
with anatomical resection of the primary tumor and system-
atic lymph node dissection. Our immediate aim was to iden-
tify variables predicting patients with N0 disease and subse-
quently to refine indications for systematic nodal resection.
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Subsequently, we investigated the utility of the predictive
factors identified in a retrospective series of nonscreening-
detected lung cancers.
PATIENTS AND METHODS
We recruited 5201 asymptomatic volunteers to our
single-center prospective COSMOS screening study in 2004
and 20052 and followed up them annually for 5 years. Those
eligible were aged 50 years or older, heavy (20 pack-years)
smokers or former heavy smokers who stopped not more than
10 years previously. All gave written informed consent to
receive annual low-dose CT for 5 consecutive years. The CT
machine was a High Speed Advantage multidetector (General
Electric, Milwaukee, WI); contrast was not used for screening
scans, which were taken in a single breath with the machine
set at 140 kVp and 30 mA, with 2.5 mm slice thickness.
Patients with suspicious lung nodules underwent FDG-
PET-CT using an in-line system (Discovery LS, GE Medical
Systems Waukesha, WI) consisting of an Advance NXi PET
scanner and an eight-slice Light Speed Plus CT scanner.
Nodules that were PET-CT positive or growing at repeat
scans underwent surgical biopsy and additional interventions.
PET findings were recorded either as maximum stan-
dard uptake value (maxSUV) of FDG or positive or negative
by visual assessment. CT-PET was considered positive if the
maxSUV was more than 2.0 in the region of interest calcu-
lated automatically on lesions identified by CT. We used this
low threshold because the consequence (treatment delay) of a
false negative was more undesirable than that of a false
positive (unnecessary biopsy or surgery).2
Patient data were recorded prospectively. In this study,
we were interested in patients with clinical stage T1-2N0M0
disease (single lung nodule 3 cm maximum diameter, with
no abnormal FDG uptake at hilar or mediastinal nodal sta-
tions) who underwent curative anatomical resection plus
systematic node dissection between 2004 and 2009. Those
with history of lung malignancy, requiring extended lung
resection (such as sleeve resection, pneumonectomy, and
chest wall resection) or who received PET-CT more than 2
months before surgery, were excluded.
Patients were fasted 6 hours, and after checking that
blood glucose was less than 150 mg/dl, they were adminis-
tered 5 MBq/kg FDG intravenously; they then waited in calm
conditions (minimum movement and no speaking) for 50 to
60 minutes. Images were acquired with a combined CT-PET
in-line system (Discovery LS, GE Medical Systems) consist-
ing of an Advance NXi PET scanner and an eight-slice Light
Speed Plus CT scanner. Patients were first positioned head-
first supine and moved to the CT scanning position. A scout
scan was acquired to define the axial imaging range, which
for whole-body CT-PET typically extended from the lower
jaw to the upper thighs. CT settings were 140 kV and 80 mA.
Patients were instructed to breathe normally.
Results for FDG-PET (as maxSUV), nodule size on
preoperative CT, position of the lesion (central or peripheral),
and nodule size at introperative pathological evaluation (us-
ing the fixed cutoff values 10 mm, more than 10 20 mm,
and more than 20 mm) were investigated together with
patient and tumor characteristics (age, sex, type of surgery,
side, site, and histology) to assess their role in predicting
lymph node status. Similar findings were then examined in an
independent series of consecutive patients with nonscreening-
detected cancers and comparable clinical characteristics who
underwent surgical resection at our institute during the same
period. In this group, PET findings were recorded either as
maxSUV (157 cases) or positive or negative by visual assess-
ment (36 cases); negative cases were assumed to have max-
SUV less than 2. All cases underwent systematic lymph node
dissection, defined as removal of hilar extrapulmonary nodes
and mediastinal nodes from stations 2, 4, 7, 8, 9, and 10 on
the right side, and stations 5 to 10 on the left, in accordance
with international guidelines.13,15 Confirmation of systematic
lymph node dissection was obtained by review of the number
of explored stations and number of lymph nodes removed
from the surgical and pathological reports. The nodule was
considered as peripheral if the center of the tumor was located
in the outer third of the lung in the transverse, coronal, or
sagittal plan.
Statistical Analysis
We used the Mantel-Haenszel 2 test for trend and
Fisher’s exact test to assess associations between lymph node
status (ordinal variables pN0, pN1, and pN2) and clinical and
pathological characteristics. We then combined the discrim-
inatory variables for lymph node status at univariate analysis
in the screening group (tumor size and positive/negative PET)
to assess their joint predictive value. Survival was repre-
sented by Kaplan-Meier curves and the log-rank test used to
assess the significance of differences in survival experience.
All tests were two sided. The analyses were performed with
SAS, version 8.2 (Cary, NC).
RESULTS
During the study period, a lung cancer was detected by
screening in 162 COSMOS patients; of these, 97 satisfied the
inclusion criteria of the present analysis. We also analyzed
193 consecutive patients with clinical stage I lung cancer not
detected by screening and treated in our Division during the
same period. Table 1 lists the clinical and pathological char-
acteristics of both groups.
In the screening group, 91 (94%) patients were N0 at
pathological examination, and six (6.2%) were N. Three
variables were associated with nodal status in the screening
group: pathological nodule size, maxSUV, and nodule loca-
tion (central versus peripheral). It is noteworthy that all
patients with maxSUV less than 2.0 (p  0.08 versus max-
SUV 2.0) or lung nodule 10 mm (p  0.027 versus
nodule 10 mm) or both—a total of 62 cases (Table 2)—
were N0 at pathological examination, whereas one patient
with peripheral nodule more than 10 mm and maxSUV less
than 2 had pN2 disease (Table 2). All other nodal metastases
occurred among the 29 patients with both nodule more than
10 mm and maxSUV 2.0. The rate of nodal involvement in
the latter group was 17.1% (six patients) (p  0.002 versus
those with maxSUV less than 2.0 or nodule 10 mm).
Radiological module size on preoperative CT was a less
reliable indicator than pathological size: two cases in the
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TABLE 1. Clinical and Pathological Characteristics of 97 Patients with Screening-Detected Stage I Lung Cancer and 193
Patients with Nonscreening-Detected Stage I Lung Cancer Who Underwent Anatomical Resection and Systematic Nodal
Dissection
Screening (N  97) Nonscreening (N  193)
pN0 pN1 pN2 pa pN0 pN1 pN2 pa
All 91 4 2 159 16 18
Sex
Men 64 2 2 102 11 6
Women 27 2 0 0.80 57 5 12 0.03
Age (yr)
60 37 1 1 43 5 8
60–69 47 2 0 74 7 6
70 7 1 1 0.55 42 4 4 0.16
MaxSUV
2 39 0 0 34 0 1
2 52 4 2 0.05 125 16 17 0.03
Clinical T
cT1 89 4 2 136 15 13
cT2 2 0 0 0.73 23 1 5 0.30
Tumor size (mm)
10 47 2 0 15 0 0
11–20 34 2 1 89 9 11
20 10 0 1 0.18 41 7 7 0.10
Missing 0 0 0 14 0 0
Type of surgery
Lobectomy 86 4 2 153 11 14
Bilobectomy 0 0 0 2 2 2
Segmentectomy 5 0 0 3 1 0
Pneumonectomy 0 0 0 ND 1 2 2 0.0002
Side
Right 56 2 2 95 9 11
Left 35 2 0 0.52 64 7 7 1.00
Site
Upper 50 4 0 109 8 10
Middle 6 0 0 12 0 1
Lower 35 0 2 35 4 4
Upper  middle 0 0 0 2 0 0
Lower  middle 0 0 0 ND 0 2 1 0.04
Missing 0 0 0 1 2 2
Location
Central 30 4 1 57 9 8
Peripheral 61 0 1 0.02 94 6 9 0.19
Pathological size (mm)
10 48 0 0 23 0 0
11–20 31 4 1 95 8 10
20 12 0 1 0.05 41 8 8 0.006
Pathological T
pT1 80 3 1 122 11 12
pT2 9 1 1 35 4 6
pT4 2 0 0 0.36 2 1 0 0.34
Histology
Squamous 10 0 2 25 3 1
Adenocarcinoma 71 4 0 96 12 17
SCLC 2 0 0 5 0 0
Carcinoid 3 0 0 24 0 0
Other 5 0 0 0.17 9 1 0 0.21
SUV 2 and pathological size 1 cm are predictive of pathological N0 disease.
a p values for sex, age, maxSUV, clinical T, tumor size, side, pathological size, and pathological T from Mantel Haenszel test for trendm, and p values for type of surgery, tumor
site, and histology from Fisher’s exact test.
ND, not done; SCLC, small cell lung cancer; SUV, standard uptake value.
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screening-detected group with maximum tumor diameter
10 mm on preoperative CT had N1 disease at definitive
pathological examination; however, in both cases, patholog-
ical size was more than 10 mm, the tumors were located
centrally, and only one peribronchial lymph node was in-
volved. Thus, these cases would not have influenced the
decision on whether to perform systematic lymph node
resection.
In the nonscreening group, nodule location was not
significantly associated with nodal status (Table 1). Fourteen
patients had negative CT-PET (by visual assessment or max-
SUV 2) and nodule 10 mm; nine had positive CT-PET
(by visual assessment or maxSUV 2) and nodule 10 mm;
and 21 had negative CT-PET and nodule more than 10 mm;
of these 43 cases, 42 (97.6%) were pN0 at pathological
examination. Among the remaining 149 cases with positive
CT-PET and nodule more than 10 mm, 33 (22%) had patho-
logical nodal involvement (p  0.001 versus the group of 43
patients).
Figure 1 suggests that the overall survival of patients
with subcentimeter or low FDG uptake nodules (curves A and
B) was better than that of patients with larger nodules and
high FDG uptake, both in screening and nonscreening-
detected tumors (curve C). The three curves did not differ
significantly for screening-detected cancers (p  0.22) but
did differ for nonscreening-detected cancers (p 0.038). The
median follow-up of all 290 patients was 2.4 years, range 0.1
to 6.8 years.
DISCUSSION
The prognosis of lung cancer is determined mainly by
the presence and extent of mediastinal lymph node involve-
ment,18 so mediastinal staging is usually considered essential
to determine treatment. Contrast-enhanced CT is useful for
noninvasive NSCLC staging but is insufficiently reliable
either for detecting or for excluding lymph node metastases.14
Histopathologic studies show that 21% of metastases occur in
normal sized lymph nodes,15 whereas no malignancy is found
in 40% of enlarged lymph nodes.16
PET with FDG provides metabolic characterization of
tissues and is the most accurate noninvasive modality avail-
able for staging mediastinal lymph nodes in lung cancer,19
being able to detect increased metabolism even in normal-
FIGURE 1. Overall survival according to metabolic activity (total standard uptake value [SUV]) and tumor size in screening-
detected and symptoms-detected tumors.
TABLE 2. Relationship of Pathological Node Status to Metabolic Activity (maxSUV) and Tumor Size in Screening-Detected
and Symptoms-Detected Tumors
Node Characteristics
Screening (n  97) Nonscreening (n  193)a
pN0 pN pN0 pN
All 91 6 (6.2%) 159 34 (17.6%)
10 mm and SUV 2 (or visually negative) 25 0 14 0
10 mm and SUV 2 (or visually positive) 23 0 9 0
10 mm and SUV 2 (or visually negative) 14 0 20 1 (4.8%)
10 mm and SUV 2 (or visually positive) 29 6 (17.1%) 116 33 (22.2%)
p (Fisher’s exact test) 0.014 0.024
In both groups, patients with both SUV 2 and pathological nodule size 10 mm are at very low risk of nodal involvement.
a In the nonscreening group, seven cases were visually negative on PET, and 29 cases were visually positive.
SUV, standard uptake value.
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sized lymph nodes20; nevertheless, the prevalence of occult
N2 disease even after negative FDG-PET at lymph node
stations is approximately 8 to 10%.20–22
With the spread of screening1–3 and consequent in-
crease in the proportion of lung cancers diagnosed at a very
early stage, the need to find a reliable method of identifying
mediastinal node involvement before node dissection (and
preferably preoperatively) has become more pressing, so as to
avoid lymph node dissection in cases with true N0 disease.
In this study, we identified two simple variables—the
metabolic activity of the lung nodule on FDG-PET-CT and its
maximum pathological diameter—significantly related to
nodal involvement in a screened population. We found that
these variables were subsequently able to predict nodal in-
volvement with high reliability in a nonscreening series with
clinical stage I lung cancers. When all 290 patients were
considered, the rate of occult nodal involvement when one
other variable was below cutoff was less than 1% (1/106),
versus 21.2% (39/184) for patients with both variables above
the cutoff. Although positive nodal status was significantly
associated with central nodule location in the screening
group, this was not the case for nonscreening patients. In this
latter group, we suggest that the larger overall nodule size
may have abolished the relationship of central location with
node positivity.
Unfortunately, preoperative lesion size on CT was less
accurate than pathological size in predicting nodal status.
Two screening-detected cancers with CT diameter 10 mm
had N1 disease, although the pathological size of these
lesions turned out to be more than 10 mm. We would,
therefore, recommend intraoperative measurement of lesion
size immediately after resection, which can be done by the
surgeon in the operating room and takes about 5 minutes, and
using this variable (together with preoperative maxSUV) to
decide whether systematic lymph node dissection should be
performed. Intraoperative measurement by the surgeon
should be close to pathological size; however, a study to
confirm this supposition is necessary, as tumor size is prone
to change after fixation.
We found, unexpectedly, that extent of surgery was
significantly related to nodal status in our nonscreened group
(Table 1) with high proportions of nodal involvement among
cases treated by pneumonectomy and bilobectomy. This is
probably a selection bias related to the retrospective nature of
the study: a less than 3-cm lesion treated by pneumonectomy
is likely to be centrally located with inherently greater risk of
nodal involvement, whereas bilobectomy is associated with
intraoperative discovery of interlobe adenopathy.
The two variables we have identified as predictors of
nodal status correlate with each other24,25; however, we found
that combining them increased the predictive value of the
test. We are also aware that, although the maxSUV cutoff of
2 was predictive in our series, SUV determination varies
between scanners and institutes, in relationship to differing
ways of estimating this variable and correcting it for con-
founding factors.25
A previous study26 found that several clinical and
pathological factors, including pathological tumor size and
maxSUV, were unrelated to the presence of occult N2.
Nevertheless, the authors adopted cutoffs of 3 cm for nodule
size and 14 for maxSUV. By contrast, on the basis of our
empirical findings, we adopted cutoffs of 10 mm for nodule
diameter and 2 for maxSUV, and these enabled us to reliably
distinguish patients with nodal involvement from those with-
out such involvement.
In the study of Ishida et al.,27 17% of 1.1 to 2 cm tumors
were associated with occult lymph node involvement,
whereas none of the tumors less than 1 cm had lymph node
involvement. Konaka et al.28 also reported absence of lymph
node metastases in subcentimeter lung cancers. The authors
of both studies27,28 concluded that lymph node dissection
could be omitted for subcentimeter cancers. By contrast,
Zhoua et al.29 found nodal metastases in 6 of 41 (15%)
patients with subcentimeter NSCLC and recommended sys-
tematic nodal dissection in the presence of subcentimeter
disease, although they considered that it might be possible to
omit dissection in female patients, those with normal carci-
noembryonic antigen, or those with ground-glass opacity
tumors or Noguchi type A or B tumors. Nevertheless, in this
study,29 preoperative PET staging was not performed, and
five cases of clinical stage II or III, disease, in which system-
atic nodal dissection is usually indicated, were included.
In addition to providing information on lymph node
status, tumor FDG uptake has also been shown to have a
prognostic role in lung cancer.4,30 In a study on screening-
detected cancers,4 maxSUV below 2.5 correlated with 100%
cancer-specific survival. This is in line with our finding of
100% survival in patients with pathological size 10 mm
(Figure 1) most of whom had maxSUV less than 2.
To conclude, our analyses of two limited series of
patients indicate that in the presence of clinical stage 1
disease, systematic lymph node dissection can be omitted if
preoperative FDG-PET-CT shows maxSUV less than 2 (or
negative visual assessment) and if maximal diameter at in-
traoperative examination is 10 mm. These results require
confirmation by further studies with long-term follow-up;
however, they suggest that these two simple variables might
be reliable predictors of lymph node involvement in early-
stage lung cancer, making it possible to avoid nodal dissec-
tion in a considerable number of patients, reducing operating
time and invasiveness, and also reducing the morbidity asso-
ciated with nodal dissection such as recurrent nerve injury
and chylothorax.6 By contrast, when both variables are above
the cutoffs identified in this study, radical lymph node dis-
section is advisable, even in clinically node-negative patients,
as the risk of occult nodal involvement is fairly high.
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